THOMSON REUTERS
CORTELLIS™

Fate Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 05-Aug-2014

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

THOMSON REUTERS

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

TABLE OF CONTENTS

Return to Table of Contents

Fate Therapeutics Inc

COMPANY OVERVIEW

Company Name	Fate Therapeutics Inc
Parent Company Name	Fate Therapeutics Inc
Website	http://fatetherapeutics.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	8
Number of Patents as Owner	26
Number of Patents as Third Party	2
Number of Deals	10
Key Indications	Stem cell transplantation,Muscular dystrophy,Muscle wasting disease,Genetic disorder,Hearing loss,Metabolic disorder,Stroke,Cardiovascular disease,Myocardial infarction,Obesity
Key Target-based Actions	Hedgehog protein stimulator,Glycogen synthase kinase-3 alpha inhibitor,MEK protein kinase inhibitor,GLI gene stimulator,Osteocalcin stimulator,Rho associated protein kinase 1 inhibitor,Wnt 7A ligand,Wnt inhibitory factor 1 stimulator,Wnt ligand,CD29 agonist,Cadherin-1 agonist,Cardiotrophin-1 ligand,Glucocorticoid agonist,POU domain 5 transcription factor 1 stimulator,Prostanoid receptor agonist,Protein kinase C stimulator
Key Technologies	Small molecule therapeutic,Haematopoietic stem cell therapy,Biological therapeutic,Allogenic stem cell therapy,Umbilical cord stem cell therapy,Systemic formulation unspecified,Pluripotent stem cell therapy,Peptide,Polynucleotide sequence,Adult stem cell therapy,Cell culture

COMPANY PROFILE

SUMMARY

Fate Therapeutics Inc, formed in November 2007 by Harvard University, Stanford University, University of Washington, the Scripps Research Institute (TSRI) and the Massachusetts General Hospital, is a biotechnology company that aims to develop small-molecules and biologicals to activate the body's existing stem cells and to create and differentiate induced pluripotent stem (iPS) cells.

COMPANY LOCATION

By November 2007, Fate had facilities in Seattle and planned to have locations in California and Massachusetts 'soon'.

ACQUISITIONS AND SPIN-OFFS

In April 2010, Fate entered into a definite agreement to acquire Verio Therapeutics. The acquisition had been approved buy the boards of both companies. Under the terms of the agreement, Fate would establish a Canadian subsidiary to continue to work on Verio's programs. At that time, no financial terms had been disclosed.

LICENSING AGREEMENTS

In July 2009, Fate Therapeutics entered into an agreement with the Regents of the University of California for exclusive intellectual property rights covering osteogenic agents, and small molecule compositions and techniques for inducing bone formation. The patents would be used to augment Fate's stem cell modulators (SCM).

EARLY R&D/TECHNOLOGY UPDATES

In October 2009, Fate and TSRI announced that they had developed a novel method of generating human induced pluripotent stem cells. The method using a combination of small molecules and was found to improve programming efficiency 200-fold and decrease time spent reprogramming.

Return to Table of Contents

In July 2009, preclinical data were presented at the 7th Annual Meeting of the International Society for Stem Cell Research in Barcelona, Spain, showing that Wnt activators induced mesenchymal stem cells to differentiate into mature bone-forming osteoblasts.

By May 2009, Fate was investigating small molecule stem cell modulators (SCM), developed using the company's adult stem cell biology engine and induced pluripotent stem (iPS) cell technology, with broad therapeutic potential in areas including regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.

In April 2009, Fate and Stemgent launched the Catalyst program to provide pluripotent stem cell platform for drug discovery and development.

FINANCIAL

In July 2014, Fate Therapeutics completed a long-term debt financing of up to $20 million.

In August 2013, the company filed a registration statement on Form S-1 with the US Securities and Exchange Commission regarding its planned IPO of shares. In October 2013, Fate reported the IPO would consist of 6,666,667 shares priced at $6.00 per share. Underwriters would be granted a 30-day option to buy 1 million additional shares. At that time, the shares began trading on the NASDAQ Global Market under the ticker symbol 'FATE'. Later that month, the company raised net proceeds of $40.4 million from closing the IPO of 7,666,667 shares of its common stock, including 1 million shares issued upon the exercise in full by the underwriters of their option to purchase additional shares.

In May 2001, Fate received an equity investment from Takeda Ventures.

In November 2009, the company raised $30 million in a series B financing round.

Return to Table of Contents

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Return to Table of Contents

Drugs by Indication Table

Indication	Active	Inactive	Total
Musculoskeletal disease	1	3	4
Neurological disease	1	2	3
Surgical procedure	1	1	2
Growth disorder	1	1	2
Metabolic disorder	1	1	2
Gastrointestinal disease	0	1	1
Otorhinolaryngological disease	1	0	1
Cardiovascular disease	0	1	1
Endocrine disease	0	1	1
Injury	0	1	1
Neoplasm	0	1	1
Genetic disorder	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Return to Table of Contents

Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	3
Discontinued	3
No Development Reported	5

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	4	0	4
Drug - Development/Commercialization License	1	0	2	0	3
Drug - Development Services	0	0	2	0	2
Drug - Funding	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	0	2
Hematological disease	0	2
Surgical procedure	1	1
Neurological disease	0	1
Genetic disorder	0	1
Immune disorder	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	1	1
Phase 1	0	3

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Return to Table of Contents

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	11	0	11
Endocrine disease	10	0	10
Gastrointestinal disease	5	0	5
Genitourinary disease	2	0	2
Growth disorder	4	1	5
Hematological disease	6	0	6
Degeneration	10	0	10
Immune disorder	3	0	3
Musculoskeletal disease	13	1	14
Neoplasm	8	0	8
Ocular disease	1	0	1
Genetic disorder	2	0	2
Metabolic disorder	5	0	5
Mouth disease	1	0	1
Neurological disease	14	1	15
Nutritional disorder	6	1	7
Respiratory disease	2	0	2
Infectious disease	1	0	1
Injury	8	1	9
Inflammatory disease	7	0	7
Otorhinolaryngological disease	1	0	1
Dermatological disease	6	0	6
Surgical procedure	8	1	9

Return to Table of Contents

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

ProHema

ProHema SNAPSHOT

Drug Name	ProHema
Key Synonyms	ProHema
Originator Company	Fate Therapeutics Inc
Active Companies	Fate Therapeutics Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Metabolic disorder;Stem cell transplantation
Target-based Actions	
Other Actions	Stem cell modulator;Anticancer;Hematopoietic stimulant
Technologies	Systemic formulation unspecified;Biological therapeutic;Allogenic stem cell therapy;Umbilical cord stem cell therapy;Haematopoietic stem cell therapy
Last Change Date	30-Jul-2014

ProHema DEVELOPMENT PROFILE

SUMMARY

Fate Therapeutics is developing ProHema, a program comprising of allogeneic umbilical cord stem cells that have been treated ex vivo with FT-1050 (dmPGE2), a small-molecule stem cell prostaglandin E2 modulator developed using the company's adult stem cell biology engine and induced pluripotent stem (iPS) cell technology, for the potential restoration of hematopoiesis following myeloablative chemotherapy for hematological malignancies,. The company is also investigating ProHema for the potential treatment of inherited metabolic disorders including lysosomal and peroxisomal storage disorders such as Hurler and Hunter syndromes, Krabbe disease and multiple leukodystrophies. In February 2012, a phase I/II trial began. In November 2012, a phase II trial was initiated ; in November 2013, full data were expected in 'mid-2015' ; in March 2014, enrollment was initiated. In June 2014, the company filed an IND for a phase Ib trial in pediatric patients with inherited metabolic disorders undergoing HSC transplant ; in July 2014, the US FDA cleared the IND and at that time, the company planned to initiate the trial in the fourth quarter of 2014.

Fate Therapeutics is also investigating FT-1050-treated bone marrow stem cells for the same indication.

ProHema DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Fate Therapeutics Inc	Stem cell transplantation	US	Phase 2 Clinical	06-Feb-2012
Fate Therapeutics Inc	Metabolic disorder	US	Discovery	17-Mar-2014

ProHema DRUG NAMES

Names	Type
FT-1050-treated umbilical cord stem cell therapy (hematopoietic stem cell engraftment), Fate Therapeutics	
ProHema	Trade Name

ProHema CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Hurler syndrome											
0	0	0	0	0	0	0	1	0	0	0	1
Hematological neoplasm											
0	0	0	0	0	0	0	1	0	0	0	1
Myelodysplastic syndrome											
0	0	0	0	0	0	0	1	0	0	0	1
Globoid cell leukodystrophy											
0	0	0	0	0	0	0	1	0	0	0	1
Hunter syndrome											
0	0	0	0	0	0	0	1	0	0	0	1
Chronic lymphocytic leukemia											
0	0	0	0	0	0	0	1	0	0	0	1
Non-Hodgkin lymphoma											
0	0	0	0	0	0	0	1	0	0	0	1
Acute myelogenous leukemia											
0	0	0	0	0	0	0	1	0	0	0	1

Return to Table of Contents

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	3	0	0	0	3

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

ProHema DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Active Deals
Total: 4

Return to Table of Contents

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Fate Therapeutics Inc	0	0	4	0	4
Boston Children's Hospital	2	0	0	0	2
Harvard Medical School	1	0	0	0	1
Massachusetts General Hospital	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	2	0	2
Patent - Exclusive Rights	1	0	1
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Fate Therapeutics Inc	3	0	3

Patents by Drug Relationship Type Chart



Return to Table of Contents

Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	2
Tentative	1

Return to Table of Contents

ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics

ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics SNAPSHOT

Drug Name	ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics
Key Synonyms	
Originator Company	Fate Therapeutics Inc
Active Companies	Fate Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Genetic disorder
Target-based Actions	Rho associated protein kinase 1 inhibitor;Glycogen synthase kinase-3 alpha inhibitor;MEK protein kinase inhibitor
Other Actions	Stem cell modulator
Technologies	Biological therapeutic;Haematopoietic stem cell therapy
Last Change Date	29-May-2014

ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics DEVELOPMENT PROFILE

SUMMARY

Fate Therapeutics is investigating combinations of pharmacologically modified hematopoietic stem cell modulators which include ROCK, GSK3 and MEK pathway inhibitors, using company's proprietary hiPSC technology, for the potential treatment of rare genetic disorders. In August 2013, the therapy was in preclinical development. In March 2014, preclinical data were published .

ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Fate Therapeutics Inc	Genetic disorder	US	Discovery	12-Aug-2013

ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics DRUG NAMES

Names	Type
ROCK, GSK3 and MEK pathway inhibitors (rare geneetic disorders), Fate Therapeutics	
pharmacologically modified hematopoietic stem cell therapy (rare geneetic disorders), Fate Therapeutics	

Return to Table of Contents

Return to Table of Contents

stem cell modulator program (hearing restoration), Fate Therapeutics

stem cell modulator program (hearing restoration), Fate Therapeutics SNAPSHOT

Drug Name	stem cell modulator program (hearing restoration), Fate Therapeutics
Key Synonyms	
Originator Company	Fate Therapeutics Inc
Active Companies	Fate Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hearing loss
Target-based Actions	
Other Actions	Stem cell modulator
Technologies	Small molecule therapeutic
Last Change Date	17-Apr-2012

stem cell modulator program (hearing restoration), Fate Therapeutics DEVELOPMENT PROFILE

SUMMARY

Fate Therapeutics was investigating small molecule stem cell modulators which act via regeneration of cochlear hair cells, for the potential treatment of hearing loss. In June 2011, the drug was listed as being in research, and hits were to be identified later . In March 2012, the program was listed as being in discovery and at that time, the company was seeking to outlicense the program ; however, by August 2013, the program was no longer listed as being under development.

stem cell modulator program (hearing restoration), Fate Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Fate Therapeutics Inc	Hearing loss	US	Discovery	23-Jun-2011

stem cell modulator program (hearing restoration), Fate Therapeutics DRUG NAMES

Names	Type
undisclosed compound (hearing restoration), Fate Therapeutics	
stem cell modulator program (hearing restoration), Fate Therapeutics	

Return to Table of Contents

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Fate Therapeutics Inc	1	0	0	0	1
US Government	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart

Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

Return to Table of Contents

FT-301

FT-301 SNAPSHOT

Drug Name	FT-301
Key Synonyms	
Originator Company	Ottawa Hospital Research Institute
Active Companies	Fate Therapeutics Inc
Inactive Companies	Ottawa Hospital Research Institute;Verio Therapeutics Inc
Highest Status	Discovery
Active Indications	Muscle wasting disease;Muscular dystrophy
Target-based Actions	Wnt 7A ligand
Other Actions	Stem cell stimulator
Technologies	Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	14-Nov-2013

FT-301 DEVELOPMENT PROFILE

SUMMARY

Fate Therapeutics, following its acquisition of Verio Therapeutics, which developed technology originated at Ottawa Hospital Research Institute, is investigating FT-301 (presumed to be VT-301), a human recombinant protein therapeutic program based on Wnt7A, a protein that stimulates satellite muscle stem cells, for the potential treatment of muscular dystrophy and muscle-wasting diseases such as sarcopenia and cachexia,. In February 2010, the drug was listed as being in preclinical development ; in June 2011, lead identification studies were underway ; in April 2013, preclinical data were reported. In June 2011, the company expected to initiate in vivo proof-of-concept studies with the lead molecule. By October 2013, two Wnt7A protein analogs have been identified for advancement into IND-enabling activities out of which one was expected to advance into phase I studies planned for 2015.

FT-301 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Fate Therapeutics Inc	Muscle wasting disease	Canada	Discovery	08-Apr-2010
Fate Therapeutics Inc	Muscular dystrophy	Canada	Discovery	30-Nov-2012
Ottawa Hospital Research Institute	Muscle wasting disease	Canada	Discontinued	04-Jun-2009
Verio Therapeutics Inc	Muscle wasting disease	Canada	Discontinued	08-Apr-2010

Return to Table of Contents

FT-301 DRUG NAMES

Names	Type
Wnt7a protein analogs (hiPSC, muscle-related diseases), Fate Therapeutics	
VT-301, Ottawa Hospital	Research Code
FT-301	Research Code

FT-301 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Fate Therapeutics Inc	0	0	2	0	2
Ottawa Hospital Research Institute	1	0	0	0	1
Stanford University	1	0	0	0	1

Return to Table of Contents

Deals by Type Chart

Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Patent - Exclusive Rights	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Fate Therapeutics Inc	1	0	1

Patents by Drug Relationship Type Chart



Return to Table of Contents

Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	1

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

Return to Table of Contents